Introduction
Doxorubicin is a cytostatic agent that is widely used in the therapy of solid and haematological malignancies including breast cancer, ovarian cancer, leukaemia or lymphoma. However, its benefit is limited by sideeffects such as suppression of haematopoiesis or nausea. In up to 10% of patients acute doxorubicin-induced cardiotoxicity occurs within days after doxorubicin administration. 1 Chronic doxorubicin-induced cardiomyopathy is less frequent but dose-dependent with a much higher incidence when cumulative doses exceeds 500 mg/m 2 .
2 Doxorubicininduced cardiomyopathy is characterized by left ventricular dilatation and loss of systolic function in mice [3] [4] [5] [6] and men. 7, 8 Some efforts have been made to develop strategies to avoid or reduce doxorubicin-induced cardiomyopathy, basically by attenuating reactive oxygen species production. 9 Today, dexrazoxane is approved but not recommended for routine use in the prevention of doxorubicin-induced cardiotoxicity. 10 In smaller trials the ACE inhibitor enalapril 7 or the betablocker carvedilol 8, 11 improved echocardiography parameters of left ventricular function or biomarker levels after doxorubicin treatment.
Antagonists of the mineralocorticoid receptor (MR) such as spironolactone or eplerenone are well established in chronic heart failure therapy. 12, 13 Results from a small clinical trial suggest a beneficial effect of spironolactone treatment on left ventricular ejection fraction in women receiving anthracyclins for breast cancer therapy. 14 Another phase 2/3
clinical trial evaluating the effect of eplerenone in women receiving doxorubicin (clinical-trials.gov identifier NCT01708798) is currently ongoing. We hypothesized that this effect is mediated directly by blockade of MR in cardiac myocytes. Thus, the aim of the present study was to evaluate the impact of MR antagonist treatment on doxorubicin-induced cardiotoxicity and to identify the role of cardiac myocyte MR using celltype specific gene targeting in a mouse model.
Methods

Doxorubicin cardiotoxicity protocols and MR antagonist treatment
Adult female C57Bl/6 wildtype mice received either a single dose of 15 mg doxorubicin/kg body weight or five weekly doses of 5 mg doxorubicin/kg body weight i.p. ( Figure 1A ). Control mice (CTRL) did not receive doxorubicin. Mice were treated with the MR antagonist eplerenone 200 mg/kg body weight/day with chow starting five days before the first injection or received regular chow ( Figure 1A ).
Generation of MR mutant mice
Cardiomyocyte-specific inactivation of the MR gene (MR MLCCre ) was achieved using a conditional MR allele (MR flox ) 15 and mice expressing
Cre recombinase under control of the atrial myosin light chain gene promoter (MLCCre) 16 on a C57Bl/6 genetic background as reported previously 17 ( Figure 3A ). Figure 3B ). All animal procedures were approved by the responsible animal care committees (Regierungspr€ asidium Freiburg, Germany, G-14/10) and they conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (8th edition, 2011).
Echocardiography and hemodynamic measurements
Echocardiography and hemodynamic measurements were conducted 12 days or 6 weeks after the first injection, respectively. Mice were anesthetized with isoflurane (2 vol% in O 2 ) and placed on a 37 C 
Histology
Hearts were fixed with 4% paraformaldehyde in phosphate-buffered saline and embedded in paraffin. Cross sections (5 mm) were stained with sirius red or wheat germ agglutinin with DAPI and analysed by morphometry as previously described. 
Isolation of cardiac myocytes
Cardiac myocytes from MR wildtype and MR MLCCre mice after doxorubicin treatment were isolated by enzymatic tissue dissociation during Langendorff perfusion 19 followed by fluorescence assisted cell sorting (FACS). Hearts were harvested after cervical dislocation and retrogradely perfused with Tyrode's solution supplemented with 25 mM 2,3-butanedione monoxime, 5 mM glucose, 100 mM CaCl 2 , 0.8 mg/mL collagenase B, 0.4 mg/mL hyaluronidase, and 3 mg/mL trypsin for 8 min. Enzymatic activity was interrupted by adding fetal calf serum and the resulting single cell suspension was centrifuged at 50 g for 15 s. The pellet was re-suspended in phosphate-buffered saline and stained with Draq5 for flow cytometry. Rod-shaped cardiac myocytes were identified by Draq5 positivity and high forward scatter area ( Figure 5A ) and width and separated using a BioRad S3 FACS sorter.
Gene expression analysis
Total RNA was prepared from ventricle samples with the RNeasy Mini Kit (Qiagen, Hilden, Germany). Quantitative real-time polymerase chain reaction was carried out as described previously. 17 Primer sequences are listed in Supplementary material online, Table S1 . For RNA-seq experiments DNA-free total RNA was isolated from purified cardiac myocytes using the DNA/RNA Micro Kit (Qiagen). For preparation of amplified cDNA the Ovation RNA-Seq System V2 Kit (NuGEN, San Carlos, CA, USA) was used. The cDNA was fragmented to 300 bp fragments and 50 ng were used for library preparation with the NEB Next V R Ultra DNA Library Prep Kit for Illumina (New England BioLabs, Ipswich, MA, USA) and amplified by fluorescence controlled PCR. Libraries were sequenced on a HiSeq 2500 (Illumina, San Diego, CA, USA) deep sequencing unit by the Max Planck Institute of Immunobiology and Epigenetics, Freiburg.
Statistical analysis and bioinformatics
Data were analysed using two-way ANOVA followed by Bonferroni post hoc tests. A P value of <0.05 was considered as statistically significant.
RNA-seq data were analysed on a Galaxy platform. 20 Reads were aligned to Mus musculus genome (mm9) using RNA-STAR 21 and transcript frequency was calculated after duplicate removal as fragments per kilobase per exon per million mapped reads (FPKM). 22 A q value of <0.05 was considered as statistically significant. Differential gene expression was visualized using heatmapper. 23 Enrichment of genes related to biological function (gene ontology) or signalling pathways (KEGG database) was analysed using ClueGO software. 24 Transcriptional vs. posttranscriptional regulation of gene expression was derived from the ratio of exonic to intronic reads per gene as previously described 25 and
analysed by t-test with Bonferroni correction for multiple comparisons. RNAseq data are available at the NCBI repository (BioProject ID PRJNA375919).
Results
Eplerenone treatment prevents doxorubicin-induced left ventricular dysfunction
Wildtype mice treated with a single high-dose injection of doxorubicin ( Figure 1A ) showed markedly reduced left ventricular ejection fraction ( Figure  1B , C, Table 1 ), contractility ( Figure 1D ) and relaxation ( Figure 1E ). Treatment with the MR antagonist eplerenone improved ejection fraction ( Figure 1B , C, Table 1 ) and contractility ( Figure 1D ) after doxorubicin injection. In order to evaluate the effect of MR inhibition on long-term doxorubicin cardiotoxicity, mice received repetitive low-dose injections of doxorubicin ( Figure 1A ). Chronic doxorubicin administration similarly impaired left ventricular function which was prevented by eplerenone treatment ( Figure 1B -E, Table 1 ). Doxorubicin treatment did not affect plasma aldosterone levels or cardiac MR expression (see Supplementary material online, Figure S1 ) in both models.
Eplerenone treatment partially protects from cardiac remodelling
Both, acute or chronic doxorubicin administration induced a decrease in ventricle weight (Figure 2A Figure 2A ). After acute doxorubicin injury cardiac myocyte cross sectional area was increased in mice treated with eplerenone when compared with untreated mice ( Figure 2B and C). Neither acute nor chronic doxorubicin treatment resulted in a significant increase of reactive oxygen species formation (see Supplementary material online, Figure S2 ) or apoptosis rate (see Supplementary material online, Figure S3 ). High-dose doxorubicin injection induced moderate interstitial fibrosis which was attenuated by eplerenone ( Figure 2D and E). After chronic doxorubicin treatment only minor interstitial fibrosis was detected without a significant benefit of eplerenone treatment ( Figure 2D and E).
Cardiac myocyte MR deletion improves left ventricular function after doxorubicin treatment
We aimed to evaluate whether the beneficial effect of MR antagonism on doxorubicin cardiotoxicity was related to direct inhibition of MR in cardiac myocytes. Therefore, we created mice with cell typespecific MR deletion from cardiac myocytes using the Cre/loxP system as reported previously ( Figure 3A ) 17 and evaluated the effect of MR deletion in the acute doxorubicin cardiotoxicity model ( Figure 3B) . Figure   3C and D, Table 2 ). Similarly, left ventricular contractility and relaxation were improved in MR-deficient mice when compared with MR wildtype mice ( Figure 3E and F, Table 2 ).
Doxorubicin induced cardiac atrophy but not fibrosis is prevented by cardiac myocyte MR deletion
The doxorubicin-induced decrease in ventricle weight was prevented in MR MLCCre mice ( Figure 4A ). Despite this apparent difference, cardiac Figure 4B and C) . Doxorubicin treatment induced moderate interstitial fibrosis irrespectively of the genotype ( Figure 4D and E).
MR deletion prevents repression of cardiac myocyte gene expression by doxorubicin
The cardiotoxicity of doxorubicin has earlier been related to a repressive effect on cardiac gene expression. In order to determine the impact of MR signalling on the cell type-specific transcriptome after doxorubicin treatment, cardiac myocytes were isolated and purified by fluorescenceassisted cell sorting ( Figure 5A ). RNA-seq revealed 210 genes down-regulated in MR wildtype but not in MR MLCCre cardiac myocytes after doxorubicin treatment when compared with untreated cardiac myocytes ( Figure  5B ). In contrast, only seven genes (Tcap, Uqcr10, Atp5e, Ndufs6, Ndufv3, Uba52, Ano10) showed a significantly lower expression in cardiac myocytes from MR MLCCre vs. MR wildtype mice after doxorubicin treatment ( Figure 5B ). Figure 5B) . Signaling pathway analysis revealed a significant enrichment (P < 0.05) of genes associated with muscle development or contraction ( Figure 5C ). Among them were ankyrin repeat domain 1 (Ankrd1), which was found 3.0-fold up-regulated in MR-deficient cardiac myocytes (q < 0.01, see Supplementary material online, Figure 5E and F) . After eplerenone treatment Ankrd1 and Nppa gene expression showed high variance without a significant regulation (see Supplementary material online, Figure S4 ).
Doxorubicin-induced repression of gene expression involves post-transcriptional regulation
Signalling pathway analysis revealed a significant enrichment (P < 0.05) of genes involved in processing of RNA, including RNA transcription, splicing, transport and stability, in MR-deficient cardiac myocytes ( Figure 5D , see Supplementary material online, Table S2 ). In order to evaluate the functional impact of this finding we analysed the transcriptional and posttranscriptional regulation of cardiac myocyte gene expression. After doxorubicin treatment the ratio of exonic to intronic reads was markedly reduced in MR wildtype when compared with MR MLCCre myocytes ( Figure 5G ).
Discussion
The main finding of this study is that MR antagonist treatment prevents doxorubicin-induced left ventricular dysfunction. Experiments in mice with cell type-specific MR deletion provide evidence that this beneficial effect is related to MR blockade in cardiac myocytes. The data presented in this manuscript extends previous studies from our lab and others using the same mouse model that show a beneficial effect of cardiac myocyte MR deletion after chronic pressure overload, 17 myocardial infarction 26 or deoxycorticosterone and high salt treatment. 27 Together with the present data from a small clinical trial exploring the effect of spironolactone in women receiving anthracyclins for breast cancer therapy 14 our findings support further clinical evaluation of MR antagonist use for the prevention of anthracyclin-induced cardiotoxicity. MR antagonist treatment or cardiac myocyte MR deletion consistently prevent left ventricular dysfunction and ameliorate decrease in ventricle weight after doxorubicin administration. In addition, pharmacological MR inhibition but not MR deletion has a modest beneficial effect on interstitial fibrosis which is in line with the finding that spironolactone attenuates doxorubicin-induced cardiac fibrosis in rats. 28 This suggests that impairment of left ventricular function by cardiac myocyte MR is mostly independent from the presence of cardiac fibrosis. We have earlier obtained similar findings in MR MLCCre mice after chronic pressure overload. 17 During the past years it became evident that MR activation exerts distinct effects in different cell types within the cardiovascular system. 29 Cardiac inflammation and fibrosis seem to be pre-dominantly regulated by MR in monocytes/macrophages 30, 31 and endothelial cells 32 rather than MR in cardiac myocytes. Most cell type-specific studies on doxorubicin cardiotoxicity focus on cardiac myocytes but a role for fibroblasts 3 or endothelial cells 33 has been described earlier. The specific role of MR in these cell types for doxorubicin cardiotoxicity has not been examined yet.
Several potential mechanisms have been proposed to be involved in doxorubicin-induced cardiotoxicity. It is widely accepted that doxorubicin induces ROS formation and mitochondrial dysfunction leading to cardiac myocyte apoptosis. 28, 34, 35 In the present study the applied doses of doxorubicin did not significantly increase cardiac ROS formation. This might be due to the different susceptibility of C57Bl/6 mice vs. other mouse strands to doxorubicin treatment. Accordingly, we observed only mild increases in interstitial fibrosis and apoptosis rate. A previous report describing the effect of spironolactone on doxorubicin-induced cardiotoxicity in rats does not comment on ROS formation. 28 Cardiac myocyte MR deletion attenuates ROS formation after myocardial infarction, 26 but whether this applies to doxorubicin-induced ROS formation remains unsolved. However, the clear depression of left ventricular function in our model indicates that additional mechanisms besides ROS formation contribute to doxorubicin cardiotoxicity which involve MR signalling. It has been described earlier that doxorubicin exerts a general repressive effect on cardiac transcription. 36 Since MR is a ligand-activated tran- MR-deficient mice showed an enhanced expression of genes related to the contractile fibre including the ANKRD1 gene. This was associated with less decrease in ventricle weight following doxorubicin administration. ANKRD1 is localized in the sarcomere closely to titin and is involved as a co-factor in the GATA4-mediated regulation of cardiac transcription. 38, 39 Reduced expression of sarcomeric genes including ANKRD1 in response to doxorubicin has been reported before. 38 However, eplerenone treatment had no significant effect on ANP or ANKRD1 expression which raises doubt whether preservation of left ventricular function is directly causally linked to the expression of these two genes. RNAseq analysis revealed a decrease in exon/intron ratio in MR wildtype vs. MR MLCCre mice. This finding indicates that doxorubicin represses cardiac myocyte gene expression by a post-transcriptional mechanism 25 which is prevented by MR deletion. This novel finding is underlined by the enhanced expression of genes involved in RNA splicing, transport and stability in MR-deficient cardiac myocytes. The knowledge on the role of post-transcriptional regulation by RNA binding proteins or splicing factors in cardiovascular disease 40, 41 is still limited. Further work will be required to evaluate its significance in doxorubicin-induced cardiotoxicity and to identify the link between MR signalling and posttranscriptional regulation.
Conclusions
We show here that (i) eplerenone prevents doxorubicin-induced left ventricular dysfunction, and (ii) this beneficial effect is related to inhibition of MR in cardiac myocytes. Further work is needed to clarify the role of posttranscriptional regulation for doxorubicin-induced cardiotoxicity. 
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